Novartis Israel’s Post

Check out my first blog on Signals Blog, covering MaRS Discovery District's recent "Women in AI" event!

Congratulations to the MIT Jameel Clinic - AI & Health on the conclusion of the MIT-Takeda Programme, with 16 publications, a patent and nearly two dozen projects focused on artificial intelligence and health. Launched in 2020, the programme supported over 80 MIT students and faculty and more than 125 Takeda researchers on 22 projects focused on topics including drug discovery and research, clinical drug development and pharmaceutical manufacturing. Discoveries and AI models that resulted from the programme’s research have already had an impact in the production of small-molecule medicines and processing injectable medicines. Another project – using AI to analyse speech – may allow for earlier detection of frontotemporal dementia, while making that diagnosis more quickly and inexpensively. Similar algorithmic analyses of speech in patients diagnosed with ALS may also help clinicians understand the progression of that disease. Though the formal programme has ended, an endowment continues to support the MIT-Takeda Fellowship for graduate students pursuing groundbreaking research related to health and AI. There have been 44 MIT-Takeda Fellows to-date. To close the programme, representatives from MIT and Takeda joined a panel to discuss the future impact of AI in healthcare, with: * Andrew Robertson, head of global regulatory policy and innovation at Takeda * Asu Ozdaglar, deputy dean of the MIT Schwarzman College of Computing and head of MIT's department of electrical engineering and computer science (EECS) * Dan Huttenlocher, dean of the MIT Schwarzman College of Computing and the Henry Ellis Warren Professor of EECS * David Goldston, director of the MIT Washington office. Read more here: https://lnkd.in/edhC35vm

🌟 Exciting Breakthrough in Parkinson's Disease Research! 🌟 Researchers from the University of Cambridge have made a groundbreaking advance in the fight against Parkinson's disease using artificial intelligence. By leveraging machine learning, they have dramatically accelerated the process of identifying potential drug therapies, making it ten times faster and a thousand times more cost-effective than traditional methods. 🔬 What used to take years, now unfolds in mere months. The team, led by Professor Michele Vendruscolo, developed a five-step machine learning approach to screen millions of compounds. Their method not only speeds up discovery but also enhances the potency of the compounds identified, with some showing promising results at significantly lower doses. 👨💻 This AI-driven approach represents a major leap forward in drug discovery, showcasing how technology can be a powerful ally in healthcare. It underscores the potential of AI to not just streamline but also innovate, offering hope not only for Parkinson's disease but for other conditions characterized by protein misfolding and aggregation. 🌍 As we look to the future, the possibilities are boundless. This is just the beginning of how AI-first strategies can transform medical research and lead to faster, more effective treatments. Let's celebrate the brilliant minds at Cambridge and their pioneering work that could one day change the lives of millions affected by Parkinson's worldwide. 🙌 If used properly artificial intelligence can benefit humanity. How we choose to use it is all on us. Be responsible! Be good! 🫡

The Chan Zuckerberg Initiative (#CZI), founded by Dr. Priscilla Chan and Mark Zuckerberg in 2015, leverages technology and community-driven solutions to address global challenges in health, education, science, and justice. A key aspect of CZI's #healthcare contribution is the Chan Zuckerberg #Biohub, established in 2016 in partnership with UCSF, Stanford University, and UC Berkeley. The Biohub fosters collaboration among scientists and engineers to develop innovative tools, including AI for #biomedical #research, enhancing imaging, #genomics, #disease #detection, and #drug #discovery. One notable project is the Human Cell Atlas, an effort to map all human body cells using advanced #AI techniques, providing insights into health and disease. AI applications in single-cell #biology, where machine learning analyzes complex data, reveal #cellular functions and disease mechanisms. CZI has numerous collaborations with academic institutions, such as the Broad Institute of MIT and Harvard, supporting AI in #genetic research. Through grant programs, CZI funds global researchers, focusing on AI tool development for #biomedical research and fostering interdisciplinary #innovation. CZI also partners with medical device companies, developing AI-powered diagnostic tools. For example, Butterfly Network’s handheld ultrasound devices improve #disease #detection accuracy. Collaborations with firms like Verily have led to tools identifying early signs of conditions like cancer. Partnerships with wearable technology firms, such as Fitbit, advance AI-enhanced devices for real-time #health #monitoring, transforming #disease #management. In the pharmaceutical sector, CZI collaborates to expedite drug discovery through AI, supporting drug candidate identification and #clinical #trial #optimization. CZI and Novartis use AI to repurpose existing drugs for new conditions, promising #rapid #responses to health threats. Promoting open science and data sharing speeds up new #treatments' development. As of 2024, CZI continues advancing healthcare, expanding Biohub initiatives to focus on #neurodegenerative and rare genetic disorders. CZI invests in AI tools to combat global health threats like antibiotic resistance. Partnerships with AI research organizations like DeepMind enhance #predictive #modeling, improving public health responses. CZI’s efforts exemplify how strategic philanthropy and technological innovation create substantial impacts in medical sciences. By integrating advanced technologies into healthcare, CZI is paving the way for a healthier, more efficient future. Health and AI professionals can gain valuable insights from CZI’s initiatives and play a role in driving these #transformative efforts. CZI’s work highlights the significant impact coordinated efforts in #technology and #science can have on global #health #outcomes. #BiomedicalResearch #AIinHealthcare #GlobalHealth #Genomics #DiseaseDetection #PrecisionMedicine #HealthInnovations

Navigating the Cutting Edge: Top Trends Shaping Biomedical and Clinical Research It is a dynamic landscape constantly pushing boundaries. Here at Scientia Nova (Pvt Ltd), we're keeping a pulse on the latest trends that are poised to transform healthcare: 1. The Rise of Precision Medicine: Moving beyond "one-size-fits-all" treatments, precision medicine leverages genetic and molecular data to tailor therapies to individual patients. This approach holds immense promise for increased treatment efficacy and reduced side effects. 2. Artificial Intelligence (AI) & Big Data Revolution: The ever-growing mountains of medical data are ripe for analysis by AI. Advanced algorithms can identify patterns, predict disease risks, and personalize treatment plans with ever-increasing accuracy. 3. Gene Editing Technologies: Tools like CRISPR-Cas9 offer the potential to revolutionize healthcare by correcting genetic defects at the source. This opens doors for treating previously untreatable genetic diseases and even preventing them in future generations. 4. Focus on the Microbiome: The trillions of microbes residing within our bodies are increasingly recognized as key players in health and disease. Research on the gut microbiome is leading to novel therapeutic strategies for digestive disorders, immune system imbalances, and even neurological conditions. 5. Cell & Gene Therapy Advancements: Techniques utilizing engineered cells or gene therapy vectors to treat diseases are showing promising results. This holds significant potential for treating cancers, neurological disorders, and inherited diseases. 6. Wearable Technology & Remote Patient Monitoring: Wearable devices and remote monitoring tools allow for continuous health data collection, enabling earlier disease detection, proactive care management, and improved patient outcomes. 7. Collaboration & Open Science: Fostering global collaboration among researchers, institutions, and pharmaceutical companies is crucial to accelerate R&D efforts and translate discoveries into real-world solutions faster. The Future of Research? These trends, along with ethical considerations and responsible clinical trial design, are shaping the future of biomedical research. At Scientia Nova (Pvt Ltd), we're actively involved in exploring these exciting avenues to make a meaningful impact on global health. What trends in biomedical and clinical R&D excite you the most? Share your thoughts and join the conversation in the comments! #biomedicalresearch #healthcare #innovation #science #futureofmedicine #precisionmedicine #AI #geneediting #microbiome #celltherapy #wearables #collaboration #medicine #research #scientianova

Call for Chapters: "Future of AI in Biomedicine and Biotechnology" Dear LinkedIn Community, We are delighted to announce a unique opportunity for experts, professionals, researchers, and enthusiasts in the fields of AI, biomedicine, and biotechnology. 📖 Book Title: Future of AI in Biomedicine and Biotechnology 🌟 About the Book: This comprehensive volume aims to shed light on the transformative potential of AI within the realms of healthcare and biotechnology. Designed for a diverse audience ranging from healthcare practitioners and researchers to policymakers and investors, the book will delve into critical areas like AI-driven drug discovery, medical imaging, personalized medicine, ethical considerations, and much more. 🖋 Editors: Dr. Shankar Khade, PhD Dr. Raj Gaurav Mishra 📅 Important Dates: Abstract Submission: January 21, 2024 Full Chapter Submission: March 17, 2024 This is an unparalleled opportunity to contribute to a seminal work that promises to shape the discourse on the future of AI in healthcare and biotechnology. We invite researchers, professionals, and thought leaders to share their expertise, insights, and innovative ideas. For detailed submission guidelines, submission, and further information, please feel free to reach out to us or visit: https://lnkd.in/dMuqkpQd Let's collaborate to pave the way for a future where AI and biomedicine synergize to revolutionize patient care, research, and beyond. Thanks and regards! #callforpapers #callforabstracts #bookchapter #scopusindexed #callforbookchapters #ai #biomedicine #aiapplications #biotechnology #aiinnovation

Trending... What is it? In healthcare, AI is transforming everything from drug development, surgical procedures to patient care. Statista reports that AI in healthcare market was worth around 11 billion U.S. dollars worldwide in 2021 and is forecasted to be worth almost 188 billion U.S. dollars by 2030. Advancements in machine learning algorithms, data accessibility, hardware affordability, and 5G connectivity are driving the widespread adoption of AI in healthcare. The Benefits : 1. Efficiency in administrative workflow 2. Optimized surgery procedures 3. Better health monitoring and preventive care 4. Data analysis and improved diagnosis 5. Reduced cost of care The Companies : Présage - Based on 4 years of clinical research, Présage is developing the 1st medical device for elderly living at home that predicts the risk of emergency hospitalization in 7-14 days. MILVUE - Milvue has developed the first Artificial Intelligence software for radiological diagnostic assistance developed by Machine Learning engineers and expert radiologists. Turing Biosystems - With focus on the problems of severe toxicities and elevated failure rates in immunotherapy, cell, and gene therapy, Turing Biosystems develops software that analyzes clinical and biological data to design treatments for patients. * Search results based in USA.

“The interface between AI and health will become essential for the care of patients in a precision medicine framework.” To debut our new blog series, 'From Slides to Devices,' Professor Bibeau discusses Owkin’s pilot program with CHU de Besançon in digital pathology and AI, and the opportunities it provides to research labs. Learn more here https://lnkd.in/enrJiDqj

Today, our Google DeepMind team is excited to introduce #AlphaProteo, our first AI system for designing novel, high-strength protein binders to serve as building blocks for biological and health research. This technology has the potential to accelerate our understanding of biological processes, aid the discovery of new drugs, the development of biosensors and more. For example, #AlphaProteo can generate new protein binders for diverse target proteins, including VEGF-A, which is associated with cancer and complications from diabetes. This is the first time an AI tool has been able to design a successful protein binder for VEGF-A. We're thrilled to be working with the scientific community to leverage #AlphaProteo on impactful biology problems and understand its limitations. We've also been exploring its drug design applications at Isomorphic Labs, and are excited for what the future holds. Check out the paper below to learn more about #AlphaProteo! #GoogleAI #GoogleResearch #GoogleDeepMind #GoogleHealth #AI #AIML https://lnkd.in/eHWjrM8N

Fascinating to see AI models collaborating for breakthroughs in biology and health. DeepMind’s latest development, AlphaProteo, showcases how AI models can build upon each other to unlock new possibilities. By using insights from AlphaFold’s protein structure predictions, AlphaProteo has been able to design novel protein binders that target specific molecules with great precision. This collaboration between different AI systems is opening up huge opportunities in fields like drug discovery, disease research, and even agriculture. For example, AlphaProteo has successfully designed binders for proteins like VEGF-A (associated with cancer and diabetes complications) and the SARS-CoV-2 spike protein, drastically improving the efficiency of research and experimentation. What’s most exciting is how this kind of AI-driven collaboration is accelerating the pace of innovation. By combining the strengths of multiple AI agents, we’re seeing breakthroughs that wouldn’t have been possible otherwise. Check out DeepMind’s article. It is worth reading. #AI #MachineLearning #ProteinDesign #Biotech #DrugDiscovery #DeepMind #AlphaProteo #Innovation #HealthTech https://lnkd.in/g5xfYwnv